Literature DB >> 1271280

Comparative actions of monomethoxyamphetamines on the release and uptake of biogenic amines in brain tissue.

L F Tseng, M K Menon, H H Loh.   

Abstract

para-Methoxyamphetamine (PMA), a known hallucinogen, is the most potent compound among methoxyamphetamines in disrupting behavior in rats. PMA, unlike d-amphetamine (A), did not induce stereotyped behavior and was less effective than A in stimulation of locomotor d-amphetamine-like effects, but ortho-methoxyamphetamine (OMA) was devoid of any locomotor stimulation. To investigate the reasons for the different behavioral effects caused by PMA, meta-methoxyamphetamine (MMA), OMA and A, a comparison was made among these drugs on the release and uptake of 3H-5-hydroxytryptamine (3H-5-HT), 3H-norepinephrine (3H-NE) and 3H-dopamine (3H-DA) in tissue slices of cerebral cortex and corpus striatum of rat brain. The potencies for the increased release of 3H-5-HT were found to be PMA greater than MMA greater than or equal to A greater than OMA in cerebral cortex of 3H-NE in cortex, A greater than or equal to PMA = MMA greater than OMA, and of 3H-DA in corpus striatum, A greater than MMA greater than PMA greater than or equal to OMA. The potencies for inhibiting the uptake of 3H-5-HT in cerebral cortex and corpus striatum were found to be PMA greater than MMA greater than A greater than OMA and of 3H-NE in cortex A greater than PMA greater than or equal to MMA greater than OMA, and 3H-DA in corpus striatum A greater than MMA greater than PMA greater than OMA. d-PMA is equipotent to l-PMA in increasing the release of 3H-5-HT but is more potent than l-PMA in blocking the uptake of 3H-5-HT. The high potency of PMA on increasing the release and inhibiting the uptake of 5-HT suggests than 5-HT may be involved in the production of hallucinogenic effects of PMA.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1271280

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Effects of stimulants, anorectics, and related drugs on schedule-controlled behavior.

Authors:  A D Harris; D Snell; H H Loh
Journal:  Psychopharmacology (Berl)       Date:  1978-01-31       Impact factor: 4.530

2.  Neuroleptic influence on hyperthermia induced by 5-hydroxytryptophan and p-methoxy-amphetamine in MAOI-pretreated rabbits.

Authors:  B Fjalland
Journal:  Psychopharmacology (Berl)       Date:  1979-05-25       Impact factor: 4.530

3.  Neurochemical and behavioural characterisation of alkoxyamphetamine derivatives in rats.

Authors:  Cesar A Romero; Diego A Bustamante; Gerald Zapata-Torres; Michel Goiny; Bruce Cassels; Mario Herrera-Marschitz
Journal:  Neurotox Res       Date:  2006-08       Impact factor: 3.911

4.  Hydroxytryptamine uptake inhibitors block para- methoxyamphetamine-induced 5-HT release.

Authors:  L F Tseng
Journal:  Br J Pharmacol       Date:  1979-06       Impact factor: 8.739

5.  Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine.

Authors:  K M Hegadoren; M T Martin-Iverson; G B Baker
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

6.  Effects of para-methoxyamphetamine and 2,5-dimethoxyamphetamine on serotonergic mechanisms.

Authors:  L F Tseng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-09       Impact factor: 3.000

7.  4-Ethoxyamphetamine: effects on intracranial self-stimulation and in vitro uptake and release of 3H-dopamine and 3H-serotonin in the brains of rats.

Authors:  K M Hegadoren; A J Greenshaw; G B Baker; M T Martin-Iverson; B Lodge; S Soin
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

8.  Backward walking and circling: behavioural responses induced by drug treatments which cause simultaneous release of catecholamines and 5-hydroxytryptamine.

Authors:  G Curzon; J C Fernando; A J Lees
Journal:  Br J Pharmacol       Date:  1979-08       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.